drugset / Trial / NCT06313593

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT06313593

Phase 1 Recruiting 186 enrolled Incyte Corporation
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

Timeline

Start
2024-08-08
Primary completion
2028-10-09
Completion
2028-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject INCB160058 Unknown Oral